Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05270681
Other study ID # 2021H0219
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 8, 2021
Est. completion date December 2024

Study information

Verified date January 2023
Source Ohio State University
Contact Raquel Minarsch, DPT
Phone 614-685-5399
Email raquel.minarsch@osumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1). A secondary aim will be to determine if a movement to music exercise program delivered via telehealth improves balance, cognition, mobility, and quality of life (Aim 2).


Description:

The purpose of this study is to determine if a movement to music exercise program created for our clinic patients, called "Move to Improve," delivered via telehealth is possible and safe for individuals with neurodegenerative disease. Investigators also hope to determine if this telehealth movement to music exercise program improves balance, cognition, mobility, and quality of life. Participants will be asked to participate in a movement to music exercise program that will be accessible by video twice a week for 12 weeks and complete assessments before starting and after completing the program. Participants will be recruited from the OSU Neurology Clinic which serves a large regional area, including rural Appalachian counties. Participants will be ages 21 or older with a confirmed diagnosis of a degenerative neurologic disorder such as Huntington's disease who can access a computer, tablet, or smartphone, can complete the exercises, and have a care partner. Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which are accessible by computer or tablet 24/7 via a hyperlink. This link will be accessible to the community. Here is a link to an example of the class lead by the instructor for this study: https://www.youtube.com/watch?v=NdoPi9YXoWg. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care givers will be also participate in the exercise class and will be present to ensure safety. The care giver and participant will be instructed to stand at a counter or behind a chair for safety during exercise. Participants within driving distance will come to the MEND lab for in-person outcome measures at baseline and after the 12 week intervention. Assessments will also be administered to all participants via telehealth. For those individuals who are not able to come to the lab for assessment due to distance or other reasons, tests will only be administered via telehealth. These individuals will be consented via phone. Telehealth exercise classes will be conducted using a virtual meeting platform such as Zoom, Microsoft Teams, or FaceTime. Caregivers will be present during all assessments to ensure safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - confirmed diagnosis of a degenerative neurologic disorder such as HD, PD, mild dementia or mild cognitive impairment - above the age of 21 years - has a care partner who can assist with the program. - able to access the online exercise program - able to understand study and provide consent. - stable medication regime for four weeks prior to initiation of trial, and anticipated to be able to maintain a stable regime for the course of trial - OR regularly assisting in the care for an individual that meet the above criteria (for care partners) Exclusion Criteria: - any physical or psychiatric condition that would prohibit the participant from completing the intervention or the full battery of assessments - unable to understand or communicate in spoken English - currently involved in any intervention trial or within four weeks of completing an intervention trial - current, regular participation in a structured exercise program three times per week or more

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Movement to Music
Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.

Locations

Country Name City State
United States The Ohio State University Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Ohio State University Huntington's Disease Society of America

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Open-ended questionnaire A survey to describe participant perceptions about the intervention at the end of the study 12 weeks
Primary Change in 4 stage balance test from baseline: feet together from baseline How long a participant can stand with feet together up to 10 seconds 12 weeks
Primary Change in 4 stage balance test from baseline: feet together from baseline - TELEHEALTH How long a participant can stand with feet together up to 10 seconds collected via telehealth 12 weeks
Primary Change in 4 stage balance test from baseline: feet staggered from baseline How long a participant can stand with feet staggered up to 10 seconds 12 weeks
Primary Change in 4 stage balance test from baseline: feet staggered from baseline - TELEHEALTH How long a participant can stand with feet staggered up to 10 seconds collected via telehealth 12 weeks
Primary Change in 4 stage balance test from baseline: feet in tandem from baseline How long a participant can stand with feet heel to toe up to 10 seconds 12 weeks
Primary Change in 4 stage balance test from baseline: feet in tandem from baseline - TELEHEALTH How long a participant can stand with feet heel to toe up to 10 seconds collected via telehealth 12 weeks
Primary Change in 4 stage balance test from baseline: single leg stance from baseline How long a participant can stand on one foot to toe up to 60 seconds 12 weeks
Primary Change in 4 stage balance test from baseline: single leg stance from baseline - TELEHEALTH How long a participant can stand on one foot to toe up to 60 seconds collected via telehealth 12 weeks
Primary Change in 5 Times Sit to Stand Test from baseline How long a participant can stand up and sit down from a standard chair with arms crossed across chest in seconds 12 weeks
Primary Change in 5 Times Sit to Stand Test from baseline - TELEHEALTH How long a participant can stand up and sit down from a standard chair with arms crossed across chest in seconds collected via telehealth 12 weeks
Primary Change in Adapted Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Questionnaire from baseline A patient-reported outcome measure that assesses perceived difficulty in completing physical tasks. 12 weeks
Primary Change in Patient Health Questionnaire (PHQ-9) from baseline A self-administered instrument for depression module, which scores each of the items as "0" (not at all) to "3" (nearly every day), with higher scores indicating worse depression 12 weeks
Primary Change in Patient Health Questionnaire (PHQ-9) from baseline - TELEHEALTH A self-administered instrument for depression module, which scores each of the items as "0" (not at all) to "3" (nearly every day), with higher scores indicating worse depression. Collected via telehealth 12 weeks
Primary Change in 12-item Self-Report World Health Organization Disability Assessment Schedule (WHODAS) 2.0 questionnaire from baseline A patient reported outcome measure containing 12 items that the participant rates his or her difficulties in maintaining personal care, occupational tasks and functioning in relation to family and society with a score range from 12 to 60, where higher scores indicate higher disability or loss of function. 12 weeks
Primary Change in 12-item Self-Report World Health Organization Disability Assessment Schedule (WHODAS) 2.0 questionnaire from baseline - TELEHEALTH A patient reported outcome measure containing 12 items that the participant rates his or her difficulties in maintaining personal care, occupational tasks and functioning in relation to family and society with a score range from 12 to 60, where higher scores indicate higher disability or loss of function. Collected via telehealth 12 weeks
Primary Change in verbal fluency from baseline A measure of cognition that involves asking the participant to name as many animals as they can in 60 seconds and then they are given a letter and asked to name all of the words that begin with that letter in 60 seconds. The more words the better the outcome. 12 weeks
Primary Change in verbal fluency from baseline - TELEHEALTH A measure of cognition that involves asking the participant to name as many animals as they can in 60 seconds and then they are given a letter and asked to name all of the words that begin with that letter in 60 seconds. The more words the better the outcome. Collected via telehealth. 12 weeks
Primary Change in Digit Span test from baseline A measure of cognition that involves asking the participant to recall a series of numbers. The more numbers recalled accurately the better the outcome. 12 weeks
Primary Change in Digit Span test from baseline - TELEHEALTH A measure of cognition that involves asking the participant to recall a series of numbers. The more numbers recalled accurately the better the outcome. Collected via telehealth 12 weeks
Secondary Change in Unified Huntington's Disease Rating Scale (UHDRS) Motor Scale from baseline UHDRS Motor Scale is administered by a trained rater who has the individual perform tasks such as tapping fingers and standing up and walking. The rater then scores performance on a scale of 0-4. Higher scores indicates worse outcomes 12 weeks
Secondary Change in Unified Huntington's Disease Rating Scale (UHDRS) Functional Assessment scale from baseline A questionnaire that participants fill out rating their difficulty dealing with life situations on a yes or no scale 12 weeks
Secondary Change in Unified Huntington's Disease Rating Scale (UHDRS) Independence scale from baseline A questionnaire that participants fill out rating their difficulty performing tasks on a scale of 10-100 with 100 indicating independence 12 weeks
Secondary Change in Symbol Digit Modality Test (SDMT) from baseline The SDMT is a part of the standard cognitive battery used with Huntington's disease that involves a simple substitution task, using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures. 12 weeks
Secondary Change in the Stroop interference test from baseline The Stroop is a part of the standard cognitive battery used with Huntington's disease that involves participants to read three different tables as fast as possible. Two of them represent the "congruous condition" in which participants are required to read names of colors (henceforth referred to as color-words) printed in black ink (W) and name different color patches (C). Conversely, in the third table, named color-word (CW) condition, color-words are printed in an inconsistent color ink (for instance the word "red" is printed in green ink). 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Not yet recruiting NCT04429230 - Non-invasive Brain Stimulation in Huntington's Disease N/A
Recruiting NCT05032196 - Study of WVE-003 in Patients With Huntington's Disease Phase 1/Phase 2
Recruiting NCT03599076 - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated NCT04617860 - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease Phase 1/Phase 2
Completed NCT05748288 - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting NCT05360082 - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting NCT04370470 - Development of Assessments for Later Stage HD
Recruiting NCT01834053 - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. Phase 1/Phase 2
Completed NCT01458470 - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease Phase 2
Completed NCT01357681 - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) Phase 2
Completed NCT00980694 - Bioavailability of Ubiquinol in Huntington Disease Phase 1
Completed NCT00146211 - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Phase 3
Recruiting NCT01412125 - Study of Biomarkers That Predict the Evolution of Huntington's Disease N/A
Completed NCT00075140 - Family Health After Predictive Huntington Disease (HD) Testing Phase 3
Recruiting NCT04818060 - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting NCT04301726 - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD Phase 1
Completed NCT03421327 - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting NCT03296176 - Metabolomic Study in Huntington's Disease (METABO-HD) N/A